PDEF is expressed in luminal epithelial cells of the prostate gland and associates with luminal phenotype. Hippo pathway regulates cell growth/proliferation, cellular homeostasis, and organ development by modulating phosphorylation of its downstream effectors. In previous studies, we observed decreased levels of PDEF during prostate cancer progression. In the present studies, we evaluated the effects of the expression of PDEF on total/phosphoprotein levels of YAP1 (a downstream effector of the Hippo pathway). We observed that the expression of PDEF in PC3 cells resulted in increased YAP1 levels and increased phospho-YAP1 (Ser127) protein. Our immunofluorescence analysis for YAP1 revealed an increased cytoplasmic/nuclear ratio of YAP1 in PDEF-PC3 cells as compared to VC-PC3 cells, suggesting PDEF may play a critical role in modulating YAP1, and by extension in the regulation of the Hippo pathway. We also observed a decrease in YAP1 protein levels in prostate cancer tissues as compared to normal prostate tissues.
Introduction:
Prostate Cancer (PCa) is the second most common cause of cancer deaths in men in the USA.
Despite advancements in the early diagnosis and treatment of localized PCa, about 31,620 men will die of PCa in 2019, mostly due to mCRPC. The progression of PCa initially depends on androgen receptor (AR) signaling. Androgen deprivation therapy (ADT) is the primary treatment option for PCa 1 . However, androgen deprivation therapy fails and leads to the development of castrate resistance prostate cancer (CRPC) which is a continuum of an advanced/aggressive stage of PCa 2 . Patients with CRPC phenotype are poor responders to available current therapy including the second-generation drugs e.g. Enzalutamide (ENZ) 3 .
PCa is associated with dysregulation of many signaling pathways. One of the important signaling pathways that control cell growth/proliferation, cellular homeostasis, and organ development, is the hippo pathway 4 . This tumor suppressor pathway was first identified in Drosophila melanogaster 5 and is highly conserved across species including humans 6 . The downstream effector of the hippo pathway is YAP (Yes-associated protein). YAP lacks a DNA-binding domain and interacts with other transcription factors such as TEAD to bind DNA and regulates gene expression 7 . Multiple signaling events such as cell-cell contact, cell density/polarization, mechnao-transduction, G-protein-coupled receptors mediated signaling regulate hippo pathway activation 8 .
Altered expression of YAP1 has been associated with many solid tumors including PCa [9] [10] [11] [12] [13] [14] [15] [16] [17] . The role of PDEF in PCa remains highly debated [18] [19] [20] [21] [22] [23] [24] [25] . We observed that PDEF suppresses EMT transition and metastasis in part by driving the expression of epithelial/luminal differentiationrelated genes 20, 24 . Present studies investigated the relationship between PDEF expression and the Hippo pathway in PCa.
We observed that the expression of PDEF in PC3 cells resulted in increased YAP1 and phospho-YAP1 protein levels. We observed a gradual decrease in YAP1 mRNA expression during prostate cancer progression (low to high Gleason grade and during metastasis). Analysis of YAP1 and PDEF in NEPC/CRPC datasets showed a further decrease in YAP1 as well as PDEF mRNA levels in NEPC as compared to CRPC. A direct correlation was observed between PDEF and YAP1 expression in the clinical data set. These exciting results show for the first time potential cross-talk between PDEF and Hippo pathway.
Results:

Expression of PDEF in PC3 cells results in increased YAP1 and phospho-YAP1 protein:
To investigate the relationship between PDEF and YAP1, levels of YAP1 total and phosphorylated protein in PDEF-PC3 cells 20 and VC-PC3 cells were analyzed by western blots. We observed PDEF-PC3 cells have a higher amount of YAP1 protein (total and phosphoprotein levels) compared to VC-PC3 cells (Figure 1 A) . Analysis by immunofluorescence (IMF) 24 images for YAP1 showed more cytoplasmic/nuclear ratio of YAP1 in PDEF-PC3 cells as compared to VC-PC3 cells (Figure 1 B) . These results are the first direct demonstration of regulation of YAP1 by PDEF in any system.
YAP1 protein levels are decreased in high-grade PCa:
To elucidate the status of YAP1 protein levels in PCa patient's sample, we analyzed the IHC images for YAP1 protein. For these studies, we analyzed data for IHC images for YAP1 protein in PCa patients with low and high-grade tumors from the free publicly available The Human Protein Atlas website 26 . We observed decreased levels of YAP1 protein in patients with high-grade 
YAP1 mRNA expression is decreased in PCa patients from different clinical cohorts:
We analyzed the multiple clinical cohorts of PCa for YAP1 mRNA expression using UALCAN 27 and c-Bioportal 28, 29 . The results revealed a significant decrease in YAP1 mRNA levels in patients with PCa (n=497) as compared to normal control (n=52) (p= 3.81E-10) (Figure 2 A) in The Cancer Genome Atlas (TCGA) data set 30 . We also analyzed YAP1 mRNA expression data for patients with different Gleason scores (GS). Compared to normal control, we found a significant decrease in YAP1 mRNA levels in all grades of PCa (GS6; p=6.12E-10, GS7; p=9.20E-10, GS8; p=6.24E-10 and GS9; p=1.75E-10) (Figure 2 
YAP1 and PDEF mRNA expression is lost in NEPC patients:
We analyzed the Neuroendocrine/Castration-Resistant Prostate Cancer dataset (NEPC/CRPC) 32 for expression of YAP1 and PDEF mRNA levels. Our analysis of NEPC/CRPC dataset revealed that expression (mRNA levels) of YAP1 and SPDEF was decreased in NEPC patients as compared to CRPC patients (Figure 3 A; Table 1 ). Furthermore, we observed a significant positive correlation (spearman p= 3.065E-4, Pearson p= 0.0227) between YAP1 and PDEF mRNA with a Spearman correlation (r) of 0.49 (Figure 3 B) . These results show for the first time that transition to NEPC is associated with complete loss of PDEF expression and suggests the plausible role of PDEF and YAP1 in the NEPC/CRPC phenotype. 
Discussion:
In the present studies, we observed that the expression of PDEF in prostate cancer cells resulted in increased protein levels of YAP1 and phospho (Ser127) YAP1. ETS transcription factors have been associated with tumor progression as well as therapy resistance in several cancers including prostate cancer. However, the role of PDEF in Prostate cancer remains debated [18] [19] [20] [21] [22] [23] [24] [25] 35, 36 . Further studies are warranted to understand the molecular mechanisms by which PDEF expression modulates Hippo signaling. Based on our results to date, we propose a working model (Figure 4) with respect to the potential mechanism by which PDEF regulates Hippo signaling.
Several studies have explored the role of YAP1 in PCa and castration-resistant prostate cancer (CRPC) [14] [15] [16] [17] . YAP1-AR axis appears to play a role in prostate cancer progression 15 . YAP regulates cell motility, invasion and castration-resistant growth of prostate cancer cells 17 . However, the present study investigated the relationship between PDEF expression and the Hippo pathway in PCa for the first time. Interestingly, PDEF is an AR co-activator and it is conceivable that PDEF plays an important role in the AR-mediated YAP1 axis. We also observed a decrease in YAP1 protein, and mRNA levels in high-grade tumors as compared to low-grade tumor samples, which parallels that of PDEF.
With the advent of next-generation AR targeted therapies (Abiraterone acetate and Enzalutamide)
there is an increasing burden of lethal therapy-resistant NEPC prostate cancer for which current treatments are ineffective 2, 3, 32 . There is an unmet need at present for the identification of molecular markers that can be exploited for diagnostic and therapeutic intervention in NEPC. Our exciting observations, that PDEF expression is completely lost in clinical specimens of NEPC patients and this parallels the loss of YAP1 expression, are tempting to speculate the role of PDEF/YAP-1 in reversing the NEPC phenotype to luminal phenotype. However, additional studies are warranted to support the reversal of the NEPC phenotype to epithelial/luminal phenotype by reactivation of the Hippo signaling.
Loss of YAP1 may lead to distorted hippo signaling and may render advanced prostate cancer impervious to the modulators of the Hippo signaling. We found that PDEF-PC3 cells have more YAP1 protein levels as compared to VC-PC3 cells, suggesting that YAP1 levels can be restored by PDEF, which may, as such, re-sensitize the advanced prostate cancers to regulators of the Hippo signaling pathway. This possibility became apparent as we also observed increased phospho-YAP1 levels, and increased cytoplasmic/nuclear ratio in PDEF-PC3 cells as compared to VC-PC3 cells, pointing to the restoration of the hippo signaling pathway in these cells upon PDEF expression. This is significant as we have demonstrated previously that PDEF promotes 
Material & Methods:
Materials:
Antibodies PDEF (sc-166846, 1:1000 dilution), GAPDH (Sigma G8795, 1:3000 dilution), YAP1
(sc-101199, 1:1000 dilution for western blots, 1:50 dilution for Immunofluorescence) and, phospho-YAP1 (cst-13008, 1:1000 dilution) were purchased from respective vendors.
Cell Lines and Culture:
We used prostate cancer cell line PC3 obtained from American Type Culture Collection (ATCC).
PC3 cell line was stably transfected with PDEF 24 and cultured as described previously 24 .
Data mining from multiple clinical cohorts:
We analyzed the YAP1 mRNA expression data from PCa TCGA 30 (The Cancer Genome Atlas) data sets through UALCAN 27 (http://ualcan.path.uab.edu/) and c-BioPortal 28, 29 (http://www.cbioportal.org) web-server. Further, we analyzed YAP1 mRNA expression in Prostate Adenocarcinoma MSKCC dataset 31 . YAP1 and SPDEF mRNA expression data were also analyzed in NEPC/CRPC dataset 32 through c-BioPortal.
Immunohistochemistry (IHC):
We procured IHC images for YAP1 protein in PCa patients with low and high-grade tumors from
The Human Protein Atlas website 26 (https://www.proteinatlas.org/ENSG00000137693-YAP1/pathology/prostate+cancer#img).
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Western blot:
Western blots for PDEF, YAP1, and Ser127-phospho-YAP1 protein were performed as described 37 . Blots were scanned by LI-COR Odyssey CLx (LI-COR, Lincoln, USA) system by using IRDye 680 goat anti-mouse/IRDye 800 goat anti-rabbit secondary antibodies as described 38 .
Immunofluorescence (IMF):
Immunofluorescence for YAP1 protein was done as described 24 .
Conclusions:
Our finding show for the first time potential regulatory role of PDEF in activation of Hippo pathway in prostate cancer. To the best of our knowledge, these results provide the first demonstration of the regulation of the Hippo pathway by PDEF in any system. 
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